Drugs / ATCell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05669261 | Aug → Dec 2023 | long COVID-19 | American CryoStem Corporation | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04744051 Comparator | Feb 2021 → Sep 2023 | traumatic encephalopathy | American CryoStem Corporation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATCell | “The proposed study is a single-site, double-blinded, placebo-controlled study involving a single administration of either individual, autologous ATCell™ lines suspended in 5%...” NCT04744051 ↗ |
| Modality | Cell therapy | “Adipose-Derived Mesenchymal Stem Cells” NCT04744051 ↗ |
| Route | Intravenous | “Via Intravenous Infusion” NCT04744051 ↗ |